During the past decade, Swiss Pharma Contract Ltd conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Swiss Pharma Contract Ltd" are "Congestive Heart Failure" (1 trials), "Hypertension" (1 trials) and "Wound Heal" (1 trials). Many other conditions were trialed in "Swiss Pharma Contract Ltd" in a lesser frequency.

Most popular intervention types in "Swiss Pharma Contract Ltd" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "BIA-5-453" (1 trials), "FSR Peptide 100μM" (1 trials), "FSR Peptide 200μM" (1 trials), "FSR Peptide 20μM" (1 trials) and "FSR Peptide 50μM" (1 trials). Other intervention names were less common.

The vast majority of trials in "Swiss Pharma Contract Ltd" are 1 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Swiss Pharma Contract Ltd". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Swiss Pharma Contract Ltd, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Swiss Pharma Contract Ltd, 2 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".